Clinical trials: Essential Hypertension.
Hypertension
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
To characterize the safety, tolerability, and efficacy profile of amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg (with optional titration to 5/80 mg) and amlodipine 5 mg monotherapy in elderly patients…
- Trial name
- NCT00699192
- Testing
- Amlodipine 5 mg, Valsartan 80 mg, Valsartan 40 mg
- Where
- 18 sites in Czechia, Finland and 8 more
- Volunteers
- 965 people
- Sponsor
- Novartis Pharmaceuticals
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function
This study will assess the dose-response effects of Inspiratory Muscle Strength Training (IMST) in adults with above-normal systolic blood pressure over a 6-week period.
- Trial name
- NCT07109739
- Testing
- POWERbreathe K5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Minnesota
Essential Hypertension
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo.
- Trial name
- hass (NCT01195805)
- Testing
- Spironolactone, Amiloride
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Regional Hospital Holstebro
Essential Hypertension
Treatment of HYpertension: Morning Versus Evening
Rationale: The nocturnal blood pressure mean is an independent and stronger predictor of cardiovascular disease (CVD) risk than either daytime office, awake or 24hour mean blood pressure.
- Trial name
- THYME (NCT02214498)
- Testing
- Enalapril/hydrochlorothiazide
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Erasmus Medical Center
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
- Trial name
- NCT07704684
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Amlodipine Group
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
- Trial name
- NCT00695955
- Testing
- Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
- Where
- 41 sites in United States, Chile and 1 more
- Volunteers
- 669 people
- Sponsor
- Takeda
Primary Hypertension
China Stroke Primary Prevention Trial
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT (NCT00794885)
- Testing
- Enalapril/folic acid, Enalapril maleate
- Where
- 2 sites in China
- Volunteers
- 20,702 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Hypertension
Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
This is an 8-week, randomized, double-blind Phase 3, multicentre study to determine the optimal dose of AZM and AML in combination therapy and to compare efficacy and tolerability of the combined therapy to each of the…
- Trial name
- NCT05385770
- Testing
- AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg
- Where
- South Korea
- Volunteers
- 890 people
- Sponsor
- Celltrion
Essential Hypertension
Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
BACKGROUND The effects of ACE-inhibitors on fibrinolysis are well documented. Experimental and clinical studies have shown that ACE inhibitors induce a reduction in plasma PAI-1 levels in many cardiovascular diseases, like…
- Trial name
- NCT00644475
- Testing
- Imidapril, Candesartan
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Pavia
Hypertension
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension
The purpose of this study is to investigate the efficacy and safety of a fixed-dose combination of perindopril 5 mg /indapamide 1.25 mg / amlodipine 5 mg compared to the free combination of the same components (perindopril 4 mg /…
- Trial name
- NCT05820880
- Testing
- Fixed [Per/Ind/Aml], Free [Per/Ind + Aml]
- Where
- 42 sites in China
- Volunteers
- 532 people
- Sponsor
- Institut de Recherches Internationales Servier
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Trial name
- NCT07660796
- Testing
- HCP1803-3, HCP1803-4, RLD2001-1
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
- Trial name
- NCT06716970
- Testing
- QR12000 75mg, QR12000 150mg, Sacubitril/valsartan 200mg
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Primary Hypertension
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
This study aims to investigate the relationship among self-efficacy, anxiety, depressive symptoms, quality of life, lifestyle, heart rate variability and blood pressure control; and to examine the effects of self-titration…
- Trial name
- NCT03470974
- Testing
- Self-titration strategy
- Where
- Taiwan
- Volunteers
- 222 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Primary Hypertension
The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble
The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity.
- Trial name
- NCT06116357
- Testing
- External Ultrasonic Micro-bubble
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Jing Huang
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Essential Hypertension
Helius in Hypertension-I: The UK Hypertension Registry
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
- Trial name
- NCT02553512
- Testing
- Ingestible Sensor and Wearable Sensor
- Volunteers
- 151 people
- Sponsor
- Proteus Digital Health, Inc.
Primary Hypertension
Automatic and Conventional Methods of Hypertensive Patients Monitoring
comparing automatic blood pressure measurments methods with conventional office methods in follow up and monitoring of hypertensive patients and predicting hypertension mediated organ damage .
- Trial name
- NCT06929728
- Testing
- blood pressure measurments devices
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Assiut University
Essential Hypertension
Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension
This study will evaluate the efficacy and safety of weak extremely low frequency electromagnetic fields (ELF-EMF) in mild and moderate essential hypertension.
- Trial name
- NCT00709930
- Testing
- Magnetic field generator
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kyoto University